Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Nephrology

Background:

• Cardiovascular disease (CVD) is a leading cause of mortality in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).
• Vascular calcification, driven by an imbalance in mineralization regulators, underlies cardiovascular events in these populations.
• Alkaline phosphatase (ALP) isozymes are critical in regulating mineralization, with tissue-nonspecific ALP (TNALP) playing a significant role in bone and vascular health.

Purpose of the Study:

• To review novel mechanisms linking ALP isozymes to vascular calcification, inflammation, and endothelial dysfunction.
• To explore the role of ALP in the cardiovascular complications of CKD and T2DM.
• To discuss emerging therapeutic strategies targeting ALP for improved cardiovascular outcomes.

Main Methods:

• Review of existing literature on ALP isozymes, vascular calcification, and cardiovascular disease.
• Analysis of experimental data on TNALP overexpression and its cardiovascular effects.
• Discussion of pharmacological approaches targeting ALP.

Main Results:

• TNALP overexpression in vasculature induces vascular calcification, cardiac hypertrophy, and premature death, mirroring CKD/T2DM cardiovascular phenotypes.
• Intestinal ALP contributes to gut mucosal defense, while intestinal and liver ALPs modulate inflammatory responses.
• A complex interplay exists between ALP, mineralization, inflammation, and endothelial function in kidney and cardiovascular diseases.

Conclusions:

• ALP isozymes are implicated in the pathogenesis of vascular calcification and associated cardiovascular complications.
• Targeting specific ALP isozymes presents a promising therapeutic avenue for managing cardiovascular risk in CKD and T2DM.
• Future drug development should aim to modulate ALP activity to improve cardiovascular outcomes without compromising skeletal health.